Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX52 Venetoclax
D10679 Venetoclax (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
BCL-2 Inhibitors
Venetoclax
D10679 Venetoclax (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10679 Venetoclax (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Cellular process
Apoptosis
BCL2* [HSA_VAR:596v1]
D10679 Venetoclax (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10679
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10679
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10679
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10679
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10679